Zidovudine use in AIDS-Free HIV-1-seropositive homosexual men in the multicenter AIDS cohort study (MACS), 1987-1989

Neil M H Graham, Scott Zeger, Victor Kuo, Lisa Paula Jacobson, Sten H. Vermund, Wohn P. Phair, Roger Detels, Charles R. Rinaldo, Alfred J. Saah

Research output: Contribution to journalArticle

Abstract

Zidovudine use data were examined in the Multicenter AIDS Cohort Study to determine (i) if the proportion of pre-AIDS participants (i.e., CD4+ cells 3 or AIDS-related complex) taking zidovudine is high enough to explain a slower than expected rise in AIDS incidence in U.S. homosexual men since mid-1987; (ii) which factors are associated with starting zidovudine and clinical trials of zidovudine; and (iii) if pre-AIDS patients, as a group, are being undertreated. Data on zidovudine use, clinical trial participation, and sociode-mographic, clinical, and hematologic variables were collected every 6 months from 1, 195 AIDS-free HIV-1-seropositive homosexual men from April 1987 to September 1989. Overall prevalence of zidovudine use rose from 3.6% in mid-1987 (visit 7) to 23% in mid-1989 (visit II). Of those with + lymphocytes/mm', the prevalence of zidovudine use rose from 23% (24% if those taking zidovudine or placebo as part of a clinical trial are included) at visit 7 to 58% (69%) at visit 11. Of those with ARC, 20% (23%) were using zidovudine at visit 7 and 55% (65%) at visit 11. Although numbers were small, the advanced ARC participants (CD4+ cells 3 and two or more symptoms) reported the highest treatment rates (50. 78, 80, 60, and 74% at visits 7-11, respectively). By September 1989, 42% (31%) of those with CD4+ lymphocyte levels 1 were still not receiving zidovudine, suggesting that many high-risk, pre-AIDS individuals are being undertreated. To explore this finding further, we examined a range of sociodemographic, hematologic, and clinical variables to determine which factors best predicted.

Original languageEnglish (US)
Pages (from-to)267-276
Number of pages10
JournalJournal of Acquired Immune Deficiency Syndromes
Volume4
Issue number3
StatePublished - 1991

Fingerprint

Zidovudine
HIV-1
Acquired Immunodeficiency Syndrome
Cohort Studies
AIDS-Related Complex
Clinical Trials
Sexual Minorities
Lymphocytes
Placebos

Keywords

  • Epidemiology
  • HIV-1
  • Homosexuality
  • Incidence
  • Pentamidine
  • Therapeutic use
  • Zidovudine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Immunology and Allergy
  • Virology

Cite this

Zidovudine use in AIDS-Free HIV-1-seropositive homosexual men in the multicenter AIDS cohort study (MACS), 1987-1989. / Graham, Neil M H; Zeger, Scott; Kuo, Victor; Jacobson, Lisa Paula; Vermund, Sten H.; Phair, Wohn P.; Detels, Roger; Rinaldo, Charles R.; Saah, Alfred J.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 4, No. 3, 1991, p. 267-276.

Research output: Contribution to journalArticle

Graham, Neil M H ; Zeger, Scott ; Kuo, Victor ; Jacobson, Lisa Paula ; Vermund, Sten H. ; Phair, Wohn P. ; Detels, Roger ; Rinaldo, Charles R. ; Saah, Alfred J. / Zidovudine use in AIDS-Free HIV-1-seropositive homosexual men in the multicenter AIDS cohort study (MACS), 1987-1989. In: Journal of Acquired Immune Deficiency Syndromes. 1991 ; Vol. 4, No. 3. pp. 267-276.
@article{78ae796935df4a02bd77f0ae8dcef1b8,
title = "Zidovudine use in AIDS-Free HIV-1-seropositive homosexual men in the multicenter AIDS cohort study (MACS), 1987-1989",
abstract = "Zidovudine use data were examined in the Multicenter AIDS Cohort Study to determine (i) if the proportion of pre-AIDS participants (i.e., CD4+ cells 3 or AIDS-related complex) taking zidovudine is high enough to explain a slower than expected rise in AIDS incidence in U.S. homosexual men since mid-1987; (ii) which factors are associated with starting zidovudine and clinical trials of zidovudine; and (iii) if pre-AIDS patients, as a group, are being undertreated. Data on zidovudine use, clinical trial participation, and sociode-mographic, clinical, and hematologic variables were collected every 6 months from 1, 195 AIDS-free HIV-1-seropositive homosexual men from April 1987 to September 1989. Overall prevalence of zidovudine use rose from 3.6{\%} in mid-1987 (visit 7) to 23{\%} in mid-1989 (visit II). Of those with + lymphocytes/mm', the prevalence of zidovudine use rose from 23{\%} (24{\%} if those taking zidovudine or placebo as part of a clinical trial are included) at visit 7 to 58{\%} (69{\%}) at visit 11. Of those with ARC, 20{\%} (23{\%}) were using zidovudine at visit 7 and 55{\%} (65{\%}) at visit 11. Although numbers were small, the advanced ARC participants (CD4+ cells 3 and two or more symptoms) reported the highest treatment rates (50. 78, 80, 60, and 74{\%} at visits 7-11, respectively). By September 1989, 42{\%} (31{\%}) of those with CD4+ lymphocyte levels 1 were still not receiving zidovudine, suggesting that many high-risk, pre-AIDS individuals are being undertreated. To explore this finding further, we examined a range of sociodemographic, hematologic, and clinical variables to determine which factors best predicted.",
keywords = "Epidemiology, HIV-1, Homosexuality, Incidence, Pentamidine, Therapeutic use, Zidovudine",
author = "Graham, {Neil M H} and Scott Zeger and Victor Kuo and Jacobson, {Lisa Paula} and Vermund, {Sten H.} and Phair, {Wohn P.} and Roger Detels and Rinaldo, {Charles R.} and Saah, {Alfred J.}",
year = "1991",
language = "English (US)",
volume = "4",
pages = "267--276",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Zidovudine use in AIDS-Free HIV-1-seropositive homosexual men in the multicenter AIDS cohort study (MACS), 1987-1989

AU - Graham, Neil M H

AU - Zeger, Scott

AU - Kuo, Victor

AU - Jacobson, Lisa Paula

AU - Vermund, Sten H.

AU - Phair, Wohn P.

AU - Detels, Roger

AU - Rinaldo, Charles R.

AU - Saah, Alfred J.

PY - 1991

Y1 - 1991

N2 - Zidovudine use data were examined in the Multicenter AIDS Cohort Study to determine (i) if the proportion of pre-AIDS participants (i.e., CD4+ cells 3 or AIDS-related complex) taking zidovudine is high enough to explain a slower than expected rise in AIDS incidence in U.S. homosexual men since mid-1987; (ii) which factors are associated with starting zidovudine and clinical trials of zidovudine; and (iii) if pre-AIDS patients, as a group, are being undertreated. Data on zidovudine use, clinical trial participation, and sociode-mographic, clinical, and hematologic variables were collected every 6 months from 1, 195 AIDS-free HIV-1-seropositive homosexual men from April 1987 to September 1989. Overall prevalence of zidovudine use rose from 3.6% in mid-1987 (visit 7) to 23% in mid-1989 (visit II). Of those with + lymphocytes/mm', the prevalence of zidovudine use rose from 23% (24% if those taking zidovudine or placebo as part of a clinical trial are included) at visit 7 to 58% (69%) at visit 11. Of those with ARC, 20% (23%) were using zidovudine at visit 7 and 55% (65%) at visit 11. Although numbers were small, the advanced ARC participants (CD4+ cells 3 and two or more symptoms) reported the highest treatment rates (50. 78, 80, 60, and 74% at visits 7-11, respectively). By September 1989, 42% (31%) of those with CD4+ lymphocyte levels 1 were still not receiving zidovudine, suggesting that many high-risk, pre-AIDS individuals are being undertreated. To explore this finding further, we examined a range of sociodemographic, hematologic, and clinical variables to determine which factors best predicted.

AB - Zidovudine use data were examined in the Multicenter AIDS Cohort Study to determine (i) if the proportion of pre-AIDS participants (i.e., CD4+ cells 3 or AIDS-related complex) taking zidovudine is high enough to explain a slower than expected rise in AIDS incidence in U.S. homosexual men since mid-1987; (ii) which factors are associated with starting zidovudine and clinical trials of zidovudine; and (iii) if pre-AIDS patients, as a group, are being undertreated. Data on zidovudine use, clinical trial participation, and sociode-mographic, clinical, and hematologic variables were collected every 6 months from 1, 195 AIDS-free HIV-1-seropositive homosexual men from April 1987 to September 1989. Overall prevalence of zidovudine use rose from 3.6% in mid-1987 (visit 7) to 23% in mid-1989 (visit II). Of those with + lymphocytes/mm', the prevalence of zidovudine use rose from 23% (24% if those taking zidovudine or placebo as part of a clinical trial are included) at visit 7 to 58% (69%) at visit 11. Of those with ARC, 20% (23%) were using zidovudine at visit 7 and 55% (65%) at visit 11. Although numbers were small, the advanced ARC participants (CD4+ cells 3 and two or more symptoms) reported the highest treatment rates (50. 78, 80, 60, and 74% at visits 7-11, respectively). By September 1989, 42% (31%) of those with CD4+ lymphocyte levels 1 were still not receiving zidovudine, suggesting that many high-risk, pre-AIDS individuals are being undertreated. To explore this finding further, we examined a range of sociodemographic, hematologic, and clinical variables to determine which factors best predicted.

KW - Epidemiology

KW - HIV-1

KW - Homosexuality

KW - Incidence

KW - Pentamidine

KW - Therapeutic use

KW - Zidovudine

UR - http://www.scopus.com/inward/record.url?scp=0025968346&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025968346&partnerID=8YFLogxK

M3 - Article

C2 - 1671411

AN - SCOPUS:0025968346

VL - 4

SP - 267

EP - 276

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 3

ER -